Fewer than one in 10 individuals that would benefit from obesity jabs like Wegovy can access them, caution the WHO as it issues its initial recommendations on the therapies.
Given in excess of 1,000,000,000 people worldwide now living with obesity, it is calling for increased and just availability to GLP-1 medication.
Based on forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"The latest guidelines affirms that excess weight is a lifelong illness that can be treated with holistic and lifelong treatment," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are key barriers to broad availability to the injections that can aid individuals in losing substantial weight, explains the body.
Skinny Jab Scarcity
Despite the present best projected case, the manufacturing of GLP-1 therapies might only reach about 100 million people – under 10% of the global need, according to the WHO.
The guideline urges nations and manufacturers to expand availability, via measures such as patent sharing.
A patent on a key compound – the core component of a leading brand – is set to lapse in a number of countries in 2026.
How Obesity Drugs Work
GLP-1 drugs imitate a body's own hormone to slow digestion, curb appetite and enhance satiety so users consume fewer calories.
Individuals usually see weight reduction within a few weeks of commencing the regular doses.
Studies points to people may regain a significant portion after a year of stopping the medication, as their typical food cravings come back.
Being overweight or obese elevates your likelihood for contracting medical conditions, including diabetes, cardiovascular issues, brain attack, and certain malignancies.
Excess weight concerns individuals in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, per the WHO.
